Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bf7f4cbc43c86dc647106f2b586ccd67c> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bf7f4cbc43c86dc647106f2b586ccd67c NCIT_P378 "NCI" @default.
- Bf7f4cbc43c86dc647106f2b586ccd67c type Axiom @default.
- Bf7f4cbc43c86dc647106f2b586ccd67c annotatedProperty IAO_0000115 @default.
- Bf7f4cbc43c86dc647106f2b586ccd67c annotatedSource NCIT_C184308 @default.
- Bf7f4cbc43c86dc647106f2b586ccd67c annotatedTarget "A radiopharmaceutical agent comprised of a pegylated cyclic arginine-glycine-aspartic acid (RGD) dimer (PRGD2) labeled with lutetium Lu 177, with potential antineoplastic activity against alphaVbeta3 integrin-expressing tumor cells. Upon administration of lutetium Lu 177 AB-3PRGD2, the RGD moiety binds to alphaVbeta3 integrin on alphaVbeta3 integrin-expressing tumor cells. The tumor cells can be eradicated upon direct cytotoxicity through beta radiation. AlphaVbeta3 integrin, a member of the integrin receptor family, is overexpressed on certain tumor cells and tumor endothelial cells while minimally or not expressed on healthy, normal cells; this receptor plays a key role in angiogenesis, tumor proliferation and survival." @default.